Cue Biopharma Launches Underwritten Public Offering with 15% Additional Shares Option

Written by Emily J. Thompson, Senior Investment Analyst

CUE-2.7%

Source: Newsfilter

Updated: Dec 18 2025

0mins

Source: Newsfilter

Public Offering Initiation: Cue Biopharma has announced the commencement of an underwritten public offering of common stock and warrants, aimed at funding its biopharmaceutical research and development, although market conditions remain uncertain.
Additional Shares Option: The company will grant underwriters the option to purchase up to an additional 15% of the shares within 30 days, enhancing its financing flexibility and potentially providing more funding for future R&D efforts.
Effective Registration Statement: The offering is conducted under an effective registration statement filed in May 2023, ensuring compliance and providing transparency for investors regarding the offering details.
Market Risk Advisory: Cue Biopharma cautions investors that the completion and terms of the offering are subject to market conditions, highlighting the potential uncertainties the company faces in financing and operations.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like CUE with instant alerts to capture every critical market movement.

CUE

$0.3613+Infinity%1D

Analyst Views on CUE

About CUE

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.